In this study, we chose the Ceacam1−/− model that develops NAFLD, insulin resistance, obesity and CVD in male Ceacam1−/− mice on normal chow starting at the age of 12–15 weeks and progressing to overt symptoms by ages >20 weeks [15,16,17,18,19]. This evidence concerns the gene CEACAM1 and metabolic dysfunction-associated steatotic liver disease.